Track topics on Twitter Track topics that are important to you
Founded in 1984, CryoLife was the first company to commercially develop the ultra-low temperature preservation of viable human heart valves for transplant. Since then, we have been engaged in an exciting transfer of technology which has led to the highly successful preservation of human saphenous and femoral veins as well as orthopaedic tissues such as tendons, menisci, and osteo-articular cartilage grafts. Today, the company holds thirteen exclusive cryopreservation patents, including the CryoSafe® triple pouch packaging system (patent #no. 5,031,762) designed to withstand ultra-cold temperatures and allow for aseptic introduction of the allograft into the sterile field.
Our laboratories and research facilities, located in suburban Atlanta, Georgia, have been designed to maximize the quality of our tissues and services. Tissue processing is conducted in a class 100 clean room environment by CryoLife technicians trained in microsurgical techniques. An in-house microbiology department performs extensive testing on each type of tissue for bacterial and fungal contamination. All donors are screened according to FDA regulations.
Our quality management system has been awarded the coveted ISO certification, an internationally recognized sign of quality assurance excellence. As a company, we are wholly committed to advancing the evolution of tissue preservation and engineering technology.
1655 Roberts Blvd., NW
United States of America
On October 10, 2017, the Hechingen-based medical device company JOTEC and the US company CryoLife signed an agreement under which CryoLife will acquire JOTEC for 225 million US Dollars, consisting of ...
ATLANTA, Oct. 10, 2017 /PRNewswire/ -- CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it h...
Medical device and tissue processing company CryoLife has agreed to acquire Germany-based Jotec for about $225m.
ATLANTA, Sept. 18, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that Pat Mac...
Medical device and tissue processing company CryoLife reached a deal to pay approximately $225 million in cash and stock for -More-
NEW YORK, NY / ACCESSWIRE / October 11, 2017 / CryoLife, Inc. (NYSE: CRY) will be discussing their earnings results in their Q3 Earnings Call to be held October 11, 2017 at 8:30 AM Eastern Time. To...
CryoLife Inc., concurrent with its $225mm cash and stock acquisition of aortic repair company Jotec, secured new $255mm credit facilities underwritten by Deutsche Bank, Capital One, and Fifth Third Ba...
CryoLife Announces Definitive Agreement to Acquire JOTEC- Provides Access into $2 Billion Global Stent Graft Market with Highly Competitive Technologically Advanced Product Portfolio- Adds Robust New ...
A 45-year-old man with acute Type A aortic dissection underwent the ascending aorta replacement with BioGlue (CryoLife Europa, Guildford, Surrey, UK) for anastomotic reinforcement. Postoperatively, he...
Founded in 1984, CryoLife was the first company to commercially develop the ultra-low temperature preservation of viable human heart valves for transplant. Since then, we have been engaged in an excit...
We have published hundreds of CryoLife Inc. news stories on BioPortfolio along with dozens of CryoLife Inc. Clinical Trials and PubMed Articles about CryoLife Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CryoLife Inc. Companies in our database. You can also find out about relevant CryoLife Inc. Drugs and Medications on this site too.
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...